Table 2. Relationship between driver mutation status and histologic subclassification of adenocarcinoma according to predominant type.
| Total | Lepidic1 | Acinar2 | Papillary | Micropapillary | Solid | Mucinous3 | p-value | |
|---|---|---|---|---|---|---|---|---|
| n (%) | 198 (100) | 11 (5.6) | 142 (71.7) | 18 (9.1) | 1 (0.5) | 17 (8.6) | 9 (4.5) | |
| Wild-type | 41 (20.7) | 3 (7.3) | 29 (70.7) | 2 (4.9) | 0 (0) | 3 (7.3) | 4 (9.8) | 0.446 Mucinous vs. others: 0.090 |
| Mutant type | 157 (79.3) | 8 (5.1) | 113 (72.0) | 16 (10.2) | 1 (0.6) | 14 (8.9) | 5 (3.2) | |
| EGFR | 124 (62.6) | 7 (5.6) | 102 (82.3) | 9 (7.3) | 1 (0.8) | 5 (4.0) | 0 (0) | < 0.001 |
| ALK | 14 (7.1) | 0 (0) | 6 (42.9) | 2 (14.3) | 0 (0) | 5 (35.7) | 1 (7.1) | 0.012 |
| KRAS | 8 (4.0) | 1 (12.5) | 1 (12.5) | 0 (0) | 0 (0) | 2 (25.0) | 4 (50.0) | < 0.001 |
| PIK3CA | 5 (2.5) | 0 (0) | 3 (60.0) | 1 (20.0) | 0 (0) | 0 (0) | 1 (20.0) | 0.31 |
| TP53 | 4 (2.0) | 0 (0) | 4 (2.8) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 |
| ERBB2 | 3 (1.5) | 0 (0) | 2 (66.7) | 0 (0) | 0 (0) | 0 (0) | 1 (33.3) | 0.272 |
| BRAF | 2 (1.0) | 0 (0) | 0 (0) | 2 (100) | 0 (0) | 0 (0) | 0 (0) | 0.043 |
| ROS1 | 2 (1.0) | 0 (0) | 0 (0) | 1 (50.0) | 0 (0) | 1 (50.0) | 0 (0) | 0.086 |
| RET | 2 (1.0) | 0 (0) | 1 (50.0) | 1 (50.0) | 0 (0) | 0 (0) | 0 (0) | 0.487 |
| NRAS | 1 (0.5) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | 1 (100) | 0 (0) | 0.192 |
1
Two cases of minimally invasive adenocarcinoma were included in the lepidic predominant type.
2
Six cases with acinar pattern showed concurrent mutation of EGFR/PIK3CA (n = 3), EGFR/TP53 (n = 1), and ALK/TP53 (n = 2).
3
Two cases of mucinous adenocarcinoma showed concurrent mutation of KRAS/PIK3CA (n = 1) and KRAS/ERBB2 (n = 1).